Pitavastatin

• UNSPSC Description:

  Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects[1][2][3][8].

• Target Antigen:

  Apoptosis; Autophagy; HMG-CoA Reductase (HMGCR); Mitophagy

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Metabolic Disease; Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/pitavastatin.html

• Purity:

  99.83

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(O)C[C@H](O)C[C@H](O)/C=C/C1=C(C2=CC=C(F)C=C2)C3=CC=CC=C3N=C1C4CC4

• Molecular Weight:

  421.46

• References & Citations:

  [7]Hayashi T, et al. A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. Atherosclerosis. 2004 Oct;176(2):255-63.|[8]Sahebkar A, et al. A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Prog Lipid Res. 2021 Nov;84:101127.|[1]Morikawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7(3):138-44.|[2]Katsuki S, et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation. 2014 Feb 25;129(8):896-906.|[3]Tajiri K, et al. Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice. Cardiovasc Drugs Ther. 2013 Oct;27(5):413-24.|[4]Hamano T, et al. Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. Neurobiol Aging. 2012 Oct;33(10):2306-20.|[5]de Wolf E, et al.Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer.Sci Rep. 2017 Jul 14;7(1):5410.|[6]Demir B, et al. The Effects of Pitavastatin on Nuclear Factor-Kappa B and ICAM-1 in Human Saphenous Vein Graft Endothelial Culture. Cardiovasc Ther. 2019 May 2;2019:2549432.Acta Biochim Biophys Sin (Shanghai). 2024 Apr 25;56(4):621-633.|Acta Pharm Sin B. 2020 May;10(5):850-860.|Biochem Pharmacol. 2019 Nov;169:113612. |bioRxiv. 2024 June 11.|J Hepatol. 2021 Aug;75(2):363-376.|Proteomics. 2023 May 4;e2300041.|Acta Biochim Biophys Sin (Shanghai). 2024 Apr 25;56(4):621-633.|Antioxidants (Basel). 2024 May 29;13(6):667.|Bioorg Chem. 2024 Apr 16:147:107369.|Research Square Preprint. 2024 Apr 9.|Sci Data. 2024 Sep 19.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  147511-69-1